KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Invested Capital: 2009-2025

Historic Invested Capital for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Sep 2025 value amounting to $17.3 billion.

  • Vertex Pharmaceuticals' Invested Capital rose 9.96% to $17.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $17.3 billion, marking a year-over-year increase of 9.96%. This contributed to the annual value of $16.5 billion for FY2024, which is 8.22% down from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Invested Capital stood at $17.3 billion for Q3 2025, which was up 0.83% from $17.2 billion recorded in Q2 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Invested Capital peaked at $18.5 billion during Q1 2024, and registered a low of $9.0 billion during Q1 2021.
  • Its 3-year average for Invested Capital is $16.5 billion, with a median of $16.5 billion in 2023.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Invested Capital spiked by 38.98% in 2021 and then decreased by 11.05% in 2025.
  • Quarterly analysis of 5 years shows Vertex Pharmaceuticals' Invested Capital stood at $10.7 billion in 2021, then soared by 34.98% to $14.4 billion in 2022, then grew by 25.19% to $18.0 billion in 2023, then fell by 8.22% to $16.5 billion in 2024, then increased by 9.96% to $17.3 billion in 2025.
  • Its Invested Capital was $17.3 billion in Q3 2025, compared to $17.2 billion in Q2 2025 and $16.5 billion in Q1 2025.